Patritumab deruxtecan

Patritumab deruxtecan
Clinical data
Other namesMK-1022
ATC code
Identifiers
CAS Number
UNII

Patritumab deruxtecan (U3-1402/ MK-1022) is an experimental antibody–drug conjugate developed by Merck and Daiichi Sankyo to treat non-small-cell lung cancer.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.